Post-earnings recap
Reported
Wed, Aug 5, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing on EPS expectations, PTC Therapeutics' stock rose by 0.99% following the earnings report. Investors may be reacting positively to management's focus on pipeline development, even in the absence of specific revenue guidance. The lack of revenue figures and prior guidance may leave some uncertainty about the company's financial trajectory.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.78 | N/A | -115.50% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced during the quarter. They emphasized their commitment to pipeline development, although no specific guidance was given.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite the current challenges.